Comorbidities and Unmet Needs Associated With Vitiligo
An expert discusses how vitiligo patients commonly develop thyroid disease as a comorbidity and face increased skin cancer risk while highlighting the urgent need for new treatments beyond the single FDA-approved ruxalitinib cream to prevent disease spread and reduce reliance on problematic steroids.
Video content above is prompted by the following:
Vitiligo’s autoimmune nature creates significant associations with other autoimmune conditions, particularly thyroid disease, which represents the most common comorbidity requiring ongoing monitoring. Dermatologists routinely perform thyroid function tests for newly diagnosed vitiligo patients and continue annual monitoring to detect developing thyroid dysfunction. This autoimmune clustering pattern reflects shared underlying immune system dysregulation that predisposes patients to multiple autoimmune conditions simultaneously.
Depigmented vitiligo patches lack protective melanin, creating substantially increased vulnerability to UV damage, sunburn and eventual skin cancer development. This heightened photosensitivity requires aggressive daily sunscreen application and sun protection measures to prevent further skin damage. Sunburn in vitiligo-affected areas can worsen the condition through additional oxidative stress, creating a cycle where sun damage both increases cancer risk and potentially expands vitiligo patches.
Despite ruxolitinib cream’s FDA approval, significant unmet needs remain in vitiligo management, particularly regarding systemic treatments to prevent disease spread. Ongoing clinical trials investigating oral JAK inhibitors offer hope for more comprehensive disease control beyond topical applications. Current reliance on steroids and immunosuppressive medications creates concerning long-term risks including serious infections, skin thinning and potential lymphoma development. Novel therapeutic approaches focusing on targeted immune modulation without broad immunosuppression represent critical areas for future drug development to address these substantial treatment gaps.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
